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TObjectives: The effect of multimodality treatment including surgical intervention,
chemotherapy, and radiation for potentially resectable stage IIIA non–small cell
lung cancer in a practice setting remains to be defined. To determine which
treatment factors are associated with improved survival, we evaluated outcomes for
these patients at our institution over a 16-year period.
Methods: We surveyed our institutional pathology database from 1986 through 2001
for patients with resected pathologic stage IIIA (N2) non–small cell lung cancer.
Three hundred fifty-three patients were confirmed to have appropriate pathologic
staging and attempted complete resection. These patients were assessed by means of
univariate and multivariable analysis for factors associated with long-term survival.
Stage migration was estimated by using a classification based on nodal station
involvement.
Results: Median potential follow-up was 132 months. During the study period, 3-
and 5-year survival increased; preoperative staging improved, relatively more
lobectomies and fewer pneumonectomies were performed, and multimodality treat-
ment was used more frequently. The number of positive N2 nodal stations did not
change over time (P  .14). Surgical intervention alone resulted in 3-year survival
of 30%, and perioperative chemotherapy, radiation, or both increased 3-year sur-
vival to 38% (P  .004). Multivariable analysis showed that male sex (hazard ratio,
1.44; 95% confidence interval, 1.13-1.84; P  .003), more than 2 positive medias-
tinal nodal stations (hazard ratio, 1.73; 95% confidence interval, 1.16-2.57; P 
.007), R1 or R2 resection (hazard ratio, 1.72; 95% confidence interval, 1.22-2.41;
P  .002), lower or middle lobe tumor location (hazard ratio, 1.63; 95% confidence
interval, 1.28-2.08; P  .001), and surgical intervention alone (hazard ratio, 1.59;
95% confidence interval, 1.23-2.04; P  .001) were independent predictors of poor
survival.
Conclusions: The use of multimodality therapy appears to contribute to improved
outcomes over time in patients with resected stage IIIA (N2) non–small cell lung
cancer.
Lung cancer continues to be the second-most common cancer and the mostfrequent cause of cancer death in the United States.1 It is estimated thatapproximately 10% to 18% of patients with non–small cell lung cancer
(NSCLC) present with stage IIIA disease with metastases to ipsilateral mediastinal
and subcarinal lymph nodes,2,3 with an expected 5-year survival of 13%.4 Optimal
treatment for this challenging group of patients remains to be defined.
Poor outcomes with surgical intervention alone in patients with stage IIIA
disease have stimulated the development of multimodality regimens incorporating
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tion therapy to improve local control. Although a few clin-
ical trials have shown improved survival with multimodality
therapy, the effect of these interventions in a cancer center
practice over time has not been extensively studied. The
purpose of this study is to determine whether outcomes in
resected stage IIIA (N2) NSCLC have improved over time
as multimodality therapy has entered clinical practice and, if
so, to ascertain what factors have brought about this im-
provement. Thus we examined our results in patients with
resected IIIA (N2) NSCLC from 1986 through 2001, spe-
cifically examining changes in treatment approaches and
patient factors over time.
Methods
Patient Population
After approval by our institutional review board, we reviewed our
institutional tumor registry for patients who had surgery for
NSCLC at the University of Texas MD Anderson Cancer Center
during the time period of January 1986 through December 2001
(n  2861). We then identified patients with resected pathologic
stage IIIA (N2) NSCLC. This list was cross-referenced with our
departmental thoracic surgery database containing prospectively
collected data from 1996 to the present. Patients were excluded if
they had carcinoid, sarcomatoid, or pure small cell histology or if
they were not pathologically proved to have N2 metastases by
means of preoperative mediastinoscopy or lymph node biopsy or
mediastinal lymph node dissection at the time of resection. All
patients were classified according to the New International Staging
System for Lung Cancer,4 irrespective of the staging system in use
at the time of the operation. The charts of the remaining 353
patients who met these criteria were further reviewed to obtain
clinical characteristics, including multimodality treatment received
at our institution or elsewhere, demographics, surgical outcome,
and survival data.
To analyze time trends in outcomes for stage IIIA lung cancer,
we reviewed our data by year from 1986 through 2001. Prelimi-
nary analysis showed more frequent use of chemotherapy in the
period from 1993 through 2001. Because of this, we divided the
study period into an early (1986-1992) and a contemporary (1993-
2001) era to evaluate other changes in treatment approach and
changes in outcomes over time.
Preoperative Assessment
Most patients were evaluated with computed tomographic scan-
ning of the chest (Table 1). Additional staging studies were per-
formed at the discretion of the surgeon or oncologist. Most patients
had functional evaluations to assess their ability to tolerate pul-
monary resection. Cervical mediastinoscopy or anterior mediasti-
notomy were also performed at the discretion of the surgeon.
Abbreviations and Acronyms
NSCLC non–small cell lung cancerPositron emission tomography was introduced late in the study
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(Table 1).
Surgical Intervention
At the time of thoracotomy, the surgeon determined the extent of
lymph node sampling or dissection that was performed. In general,
levels 2, 4, 7, 8, 9, and 10 were removed during right thoracotomy,
and levels 5, 6, 7, 8, 9, and 10 were removed during left thora-
cotomy. The pathologist examined levels 11 and higher in the
course of processing the surgical specimen.5
Follow-up
Patients were followed after resection at 1 month postoperatively,
then every 6 months for 2 years, and then annually thereafter or as
indicated by changes in clinical status. Chest radiographs were
obtained at each follow-up visit, and further testing was performed
as indicated by symptoms, signs, or abnormal chest x-ray findings.
Statistical Analysis
Association between categorical variables was assessed by using
the 2 analysis or the Fisher exact test. Nonnormally distributed
samples were compared with Mann-Whitney nonparametric anal-
ysis. Survival was estimated from the date of surgical intervention
to the date of death or from the date of treatment initiation for
patients who received induction treatment and graphically dis-
played by using the Kaplan-Meier method. All-cause mortality
was used as the end point of primary interest. Independent predic-
tors for survival were determined by using univariate followed by
multivariable Cox regression analysis, with Wald stepwise back-
ward elimination. The final multivariable model includes year of
operation and Zubrod performance status, which were included on
the basis of potential prognostic importance, even though they
were not statistically significant. Patients who died perioperatively
were included in all analyses to account for treatment-related
effects. Data entry and analysis were performed with SPSS (Chi-
cago, Ill) software, version 13.0.
Results
Patient demographics and outcomes by time period are
listed in Table 1. Mean age increased, yet overall perfor-
mance status improved from the early to the contemporary
time period. There was a 2-fold increase in use of medias-
tinoscopy over the study period. However, many patients
did not have mediastinoscopy. This could result in misclas-
sification of disease as p-stage IIIA, when it is in fact stage
IIIB by virtue of N3 disease. We compared the rate of
locoregional recurrence between those who had mediasti-
noscopy and those who did not because undiagnosed N3
disease would be expected to cause mediastinal or supra-
clavicular recurrence. We found no significant difference in
recurrence in the mediastinum (P  1.0) or the supracla-
vicular region (P  .52). Despite increased use of medias-
tinoscopy and technologic improvements in the precision of
computed tomographic scans, there were still a large num-
ber of patients whose disease was incorrectly staged as
clinical N0 (85/159 [53.5%] in the early time period and
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Significantly more patients underwent lobectomy, with
fewer subanatomic resections and fewer pneumonectomies
in the contemporary era.
Multimodality Therapy
There was a statistically significant increase over time in the
number of patients receiving multimodality therapy, partic-
ularly in the use of chemotherapy preoperatively or postop-
TABLE 1. Patient demographics and outcomes by time pe
Characteristic 1986–1992
Operations/y 2
Median potential follow-up (mo) 17
Sex (% male) 6
Mean age (y) 6
Performance status
0 22 (
1 120 (
2 17 (
Staging
CT scan of chest 156 (
Mediastinoscopy 26 (
PET scan
Histology
Squamous 50 (
Adenocarcinoma 91 (
Large cell 6 (
Other 12 (
Treatment scheme
Surgical intervention alone 64 (
Surgical intervention  XRT† 72 (
Surgical intervention  chemotherapy  XRT‡ 23 (
Type of resection
Wedge or segmentectomy 18 (
Lobectomy 86 (
Pneumonectomy 55 (
Tumor location
Upper lobe 79 (
Lower or middle lobe 80 (
30-day mortality 6 (
Completeness of resection§
R0 132 (
R1 23 (
R2 4 (
Survival
Median (mo) 1
3-y 2
5-y 1
CT, Computed tomography; PET, positron emission tomography; XRT, radia
group had postoperative radiation therapy. ‡Includes the following subset
listed in sequence of delivery): CS, 8 (2%); CSC, 7 (2%); CSCX, 8 (2%); CSX
removal of all detectable disease, negative tissue margins. R1 resection: all
disease after attempted resection.eratively (Table 1). Chemotherapy was given in the follow-
The Journal of Thoracicing sequences: 38 patients treated preoperatively, 16 treated
preoperatively and postoperatively, and 27 treated postop-
eratively. Actual treatment sequences and agents varied;
however, most patients treated with chemotherapy received
a platinum agent (82.6% in the early period and 87.9% in
the contemporary period, P .50). Only 4 patients received
preoperative radiation therapy (median dose, 45 Gy). One
hundred fifty-six patients underwent radiation therapy post-
159 1993–2001, n  194 Total, n  353 P value*
21.6 22.1 NA
89.3 131.8 NA
55 59 .09
63.9 62.5 .005
.001
40 (21%) 62 (18%)
151 (78%) 271 (77%)
3 (2%) 20 (6%)
194 (100%) 350 (99%) .09
62 (32%) 88 (25%) .001
10 (5%) 10 (3%) .003
.78
59 (30%) 109 (31%)
116 (60%) 207 (59%)
9 (5%) 15 (4%)
10 (5%) 22 (6%)
.001
52 (27%) 116 (33%)
84 (43%) 156 (44%)
58 (30%) 81 (23%)
.001
13 (7%) 31 (9%)
148 (76%) 234 (66%)
33 (17%) 88 (25%)
.95
97 (50%) 176 (50%)
97 (50%) 177 (50%)
9 (5%) 15 (4%) .70
.16
174 (90%) 306 (87%)
16 (8%) 39 (11%)
4 (2%) 8 (2%)
.019
26.6 21.8
41%
25%
erapy. *P value for comparison of the 2 time periods. †All patients in this
chemotherapy, X  radiation therapy, S  surgical intervention; initials
8%); CXS, 3 (1%); CXSC, 1 (0.3%); SC, 7 (2%); SCX, 20 (6%). §R0 resection:
disease removed but tissue margins positive. R2 resection: gross residualriod
, n 
2.7
8.5
4
0.9
14%)
76%)
11%)
98%)
16%)
0
31%)
57%)
4%)
8%)
40%)
45%)
15%)
11%)
54%)
35%)
50%)
50%)
4%)
83%)
14%)
3%)
9.2
8%
8%
tion th
s (C 
, 27 (
grossoperatively (median dose, 55 Gy).
and Cardiovascular Surgery ● Volume 130, Number 6 1603
General Thoracic Surgery Martin et al
G
TSTreatment Outcomes
Overall survival improved significantly (P  .019) over the
course of the study (Figure 1 and Table 1). Perioperative
mortality was unchanged between the 2 time periods. There
was an increased frequency of complete resection, but this
did not reach statistical significance (P  .16). Univariate
followed by multivariable analysis for survival was per-
formed to identify factors leading to improved survival
(Table 2). Variables included in the model are listed in the
table footnote. Female sex, upper lobe tumor location, any
additional chemotherapy or radiation (compared with sur-
gical intervention alone), complete resection, and involve-
ment of only one N2 nodal station were all highly signifi-
cant independent predictors of improved survival.
These prognostic factors were further examined with
respect to long-term survival. Factors related to lymph node
staging and their changes over time are shown in Table 3.
There was no difference in the number of nodes or the
number of stations sampled over time by means of thora-
cotomy. An average of 1.4 N2 stations were involved with
tumor for each patient, and this was unchanged over the
study period. On the basis of these results, pathologic stage
migration does not appear to have occurred over the course
of the study. There were more patients with extracapsular
extension of tumor in at least one lymph node in the earlier
time period (P .044); however, this was not an independent
predictor of survival by multivariable analysis (Table 2). Sur-
Figure 1. Survival by time period comparing 159 patien
1993 through 2001 (contemporary era). Ninety-five per
through 2001; dashed lines, 1986 through 1992.vival outcome stratified by number of N2 stations with
1604 The Journal of Thoracic and Cardiovascular Surgery ● Decmetastatic cancer are shown in Figure 2. Median survival
was statistically significantly improved (P  .001) when
only 1 station was involved (1 station, 25.3 months; 2
stations, 16.8 months; 2 stations, 15.5 months). Of note,
TNM stage distribution was unchanged over time (P  .16)
and similar by treatment group (P  .15), and therefore
these improvements are unlikely to be due to changes in T
status. In addition, patients with left upper lobe tumors and
nodal involvement of levels 5, 6, or both (n  21) were
evenly distributed between time periods (early, n  10;
contemporary, n 11; P .81), and their survival (median,
23.8 months) did not differ significantly compared with that
of the rest of the patients (n  332; median, 21.6 months;
P  .70).
Survival outcomes by treatment group are displayed in
Figure 3. Median survival improved significantly from 15.9
months for surgical intervention alone to 25.3 months with
the addition of multimodality therapy; 3- and 5-year sur-
vival rates increased from 30% and 17% to 38% and 24%,
respectively (P  .004). To further evaluate the effect of
chemotherapy, we compared patients who received periop-
erative chemotherapy with those who had resection alone
(Figure E1); median survival increased to 31.1 months
when patients received chemotherapy compared with resec-
tion alone (15.9 months, P  .004). We compared resection
alone with resection followed by radiation therapy (without
m 1986 through 1992 (early era) and 194 patients from
confidence intervals are displayed. Solid lines, 1993ts fro
centchemotherapy, Figure E2); median survival increased from
ember 2005
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survival with resection alone over time to ascertain whether
the natural history of the disease had changed over the
15-year period; no difference was identified (P  .217).
Figure E3 shows survival by extent of resection. Patients
with R0 resection had a median survival of 23.8 months
compared with 14.4 months for those with R1 or R2 resec-
tion (P  .001).
Discussion
By evaluating our results over time, we have shown that
outcomes in patients with p-stage IIIA (N2) NSCLC have
improved over the study period. The independent predictors
of survival, ie, sex, completeness of resection, tumor lobe
location, and extent of N2 disease have previously been
identified as prognostic factors3,6,7 and were confirmed in
our cohort. Moreover, we have shown that the addition of
chemotherapy or radiation therapy to resection for patients
with p-stage IIIA (N2) disease independently predicted en-
TABLE 2. Multivariable analysis for survival
Frequency HR
95% CI
for HR P value
Sex .01
Female (reference) 144 1.0
Male 209 1.38 1.08-1.77
Tumor lobe .001
Upper (reference) 176 1.0
Lower or middle 177 1.68 1.31-2.15
Treatment .001
Surgical intervention
only (reference) 116 1.0
Surgical intervention 
postoperative XRT 156 0.65 0.49-0.85 .002
Surgical intervention 
chemotherapy  XRT 81 0.68 0.48-0.97 .03
Extent of resection .004
R0 (reference) 306 1.0
R1-R2 47 1.66 1.17-2.34
Positive N2 nodal stations .002
1 (reference) 239 1.0
2 78 1.66 1.25-2.22 .001
2 33 1.60 1.06-2.41 .03
0 (downstaged) 3 0.79 0.19-3.26 .74
Year of operation* 353 0.98 0.95-1.005 .10
Zubrod performance status .30
0 (reference) 62 1.0
1 271 0.91 0.65-1.26 .57
2 20 1.32 0.75-2.31 .33
Other potentially prognostic variables included in univariate analysis that
did not achieve statistical significance on multivariable analysis are tumor
side, type of resection, tumor histology, age, and extracapsular nodal
extension. HR, Hazard ratio; CI, confidence interval; XRT, radiation therapy.
*Analyzed as a continuous variable.hanced survival. When we compared patients who had
The Journal of Thoracicpreoperative or postoperative chemotherapy with those
treated with surgical intervention alone, we found the sur-
vival benefit persisted and was even more marked. Further
analysis of subgroups of chemotherapy-treated subjects was
not performed because of the small sample size and heter-
ogeneity of these subgroups (Table 1, footnote).
Surprisingly, the type of resection did not affect survival
on univariate or multivariable analysis. Others have re-
ported increased mortality rates associated with pneumo-
nectomy after induction therapy.8 Of 89 pneumonectomies
in our cohort, perioperative mortality was 9%; there was
only one death in 13 patients who had preoperative therapy
followed by pneumonectomy (7.7% mortality in this
subset).
We considered the possibility of stage migration as an
explanation for the survival improvement observed. This
could result from categorization of patients with N3 or M1
disease as having IIIA cancer because of inaccurate staging
in the early era, resulting in diminished survival for stage
IIIA cancer compared with the contemporary era with more
accurate staging. When we examined the extent of lymph
node dissection and compared these results across time
periods, no differences were noted, suggesting that stage
migration did not occur. In addition, if staging accuracy had
changed markedly over the course of this study, one would
expect the outcomes of patients treated with surgical inter-
vention alone to improve in the contemporary cohort; how-
ever, no differences were found in survival. Stage migra-
tion might be contributory to the improved survival we
observed over time, but we were unable to demonstrate
its occurrence.
Alterations in survival over time might occur as a result
of inclusion of an increased proportion of lower-risk pa-
tients (in terms of tumor-related factors) in the contempo-
rary time period. Patients with left upper lobe tumors and
involvement of only level 5 or 6 nodes have been shown in
several studies to have improved prognosis, behaving more
like N1 disease.6,9-11 There were 21 patients in our study
who met this criterion, and they were evenly distributed in
the 2 time periods. Furthermore, there was no difference
when comparing their survival with that of the rest of the
cohort. This supports previous findings published by Wa-
tanabe and colleagues.12
The question remains as to what is the best approach to
patients with IIIA (N2) disease in a practice setting. That is,
what approach offers maximal effectiveness (ie, “results
achieved in the actual practice of healthcare with typical
patients and providers”13). Our study offers insight into
what can be accomplished when multimodality care is ap-
plied in a cancer center practice. An extensive research
effort in multimodality therapy has been mounted over the
last 15 to 20 years, with mixed success in improving sur-
vival. One of the first modalities used in the surgical adju-
and Cardiovascular Surgery ● Volume 130, Number 6 1605
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studies have not shown any enhancement of survival for
pN2 disease but have shown decreased rates of local recur-
rence.14-16 Surprisingly, our results show that postoperative
Figure 2. Survival by number of N2 nodal stations containing
tumor (1 vs 2 vs >2). Two hundred thirty-nine patients had
single-station N2 involvement, 78 had 2 N2 stations involved, and
33 had more than 2 N2 stations involved with tumor.
Number at risk
0 mo 12 mo 24 mo 36 mo 48 mo 60 mo
1 station 239 177 119 82 53 43
2 stations 78 47 29 19 9 5
TABLE 3. Lymph node data at thoracotomy by time period
Characteristic 1986–19
Total no. of nodes retrieved per patient, mean
(95% CI); median 15.7 (14.3–17
No. of nodal stations sampled per patient, mean
(95% CI); median 4.5 (4.3–4.7
N1 1.5 (1.3–1.6
N2 3.1 (2.9–3.2
N3 0.35 (0.09–0.
Positive N2 stations per patient, mean (95% CI);
median 1.5 (1.4–1.6
No N2 disease† 1 (0.1%)
Single-level N2 disease 104 (66%)
Two levels of N2 disease 35 (22%)
2 levels of N2 disease 19 (12%)
Nodal extracapsular invasion present, n (%) 41 (26)
CI, Confidence interval. *P value for comparison of the 2 time periods. †Th
all N2 nodal disease had resolved. The final pathologic stages were T1 N
analysis. §P value from 2 analysis. From patients who had mediastinosco
2001 time period.2 stations 33 18 7 4 3 2
1606 The Journal of Thoracic and Cardiovascular Surgery ● Decradiation therapy was associated with improved survival
relative to surgical intervention alone. The study by Keller
and associates17 also documented favorable survival rates
for surgical intervention followed by radiation therapy (39
months), which were much higher than expected with sur-
gical intervention alone, but this study included patients
with stage II and T3 N1 disease. There is general agreement
that adjuvant radiation therapy is an appropriate therapeutic
alternative to observation in patients with p-stage IIIA (N2)
disease to decrease local recurrence, whereas a definitive
answer regarding survival benefit remains to be determined.
Induction chemotherapy versus surgical intervention
alone has been tested in 4 randomized controlled trials for
stage IIIA NSCLC. Two trials demonstrated survival benefit
with chemotherapy,18-21 and 2 other studies did not show a
difference.22,23 The earlier trials included patients with T3
N0 M0 disease, and all 4 studies involved small numbers of
patients (27-62 patients per study), limiting the power to
show a difference between the study arms. A recent study
with larger enrollment (355 patients) evaluated stages I
through IIIA NSCLC24 and showed survival improvement
in stages I and II disease, but subset analysis was unable to
demonstrate an advantage to induction chemotherapy in
patients with IIIA disease (hazard ratio, 1.04; 95% confi-
dence interval, 0.68-1.60).
When N2 disease is not discovered preoperatively, con-
sideration should be given to adjuvant chemotherapy. How-
ever, chemotherapy is often not well tolerated after lung
resection.25 Many trials report administration of only 60%
of the intended dose.26 Randomized trials of adjuvant che-
motherapy in the 1990s did not show improvement in sur-
vival; however, a meta-analysis looking at platinum-based
1993–2001 Total P value*
4.0 16.2 (15.6–17.3); 14.5 15.9 (15.1–16.8); 14.0 .56‡
4.6 (4.4–4.7); 5.0 4.5 (4.4–4.7); 5.0 .58‡
1.6 (1.5–1.7); 2.0 1.5 (1.4–1.6); 1.0 .16‡
3.0 (2.9–3.1); 3.0 3.0 (2.9–3.1); 3.0 .68‡
0.71 (0.54–0.88); 1.0 0.60 (0.46–0.75); 0 .01‡
1.4 (1.3–1.5); 1.0 1.4 (1.3–1.5); 1.0 .14‡
2 (0.1%) 3 (0.1%) NS§
135 (70%) 239 (68%) .31§
43 (22%) 78 (22%)
14 (7%) 33 (9%)
33 (17) 74 (21) .04§
tients had N2 disease at mediastinoscopy. After induction chemotherapy,
, T1 N1 M0, and T2 N1 M0. ‡P value from Mann-Whitney nonparametric
 26 in the 1986 through 1992 time period and n  62 in the 1993 through92
.0); 1
); 5.0
); 1.0
); 3.0
6); 0
); 1.0
ree pa
0 M0
py: nregimens showed a trend toward survival benefit,27 which
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center trials.28-31 The recent IALT study28 showed an over-
all survival benefit for adjuvant chemotherapy that was
greatest for patients with stage III disease, whereas the
ALPI study29 was unable to achieve a significant survival
advantage. Two other multicenter trials30,31 have shown
survival advantages with adjuvant chemotherapy in early-
stage NSCLC. These trial results suggest that adjuvant
chemotherapy should be considered in all patients (p-stage
IB-IIIA) as a standard of care. Questions concerning the
timing of chemotherapy in relation to tumor resection re-
main. Our standard practice is to recommend induction
chemotherapy for patients with stage IIIA disease, but fur-
ther clinical investigations into the timing of chemotherapy
are warranted.
Although this study describes the evolution of outcomes
for patients with p-stage IIIA (N2) NSCLC and the positive
effect of multimodality therapy, important limitations re-
main. Our study is retrospective. Because treatment was
assigned on the basis of clinician judgment, selection bias is
of concern; we attempted to minimize this bias by control-
ling for other prognostic factors in multivariable analysis.
Second, because all patients with lung cancer presenting
to our institution are not enrolled in a study or entered in a
database, it is difficult to know the true denominator of
patients with IIIA disease. We chose to use pathologic
staging for identifying IIIA (N2) disease because of the
Figure 3. Survival by treatment group (surgical interv
treatment [n  237]). Ninety-five percent confidence in
erative treatment; dashed lines, surgical interventioninaccuracy of clinical staging, but this does create pitfalls.
The Journal of ThoracicWe are likely to miss 2 main groups: those patients with N2
metastases who were downstaged by induction therapy and
did not have pathologic evidence of N2 disease at resection,
and those who were considered inoperable because of phys-
iologic status or bulky N2 disease. Only 3 patients were
identified in our study who had resolution or decrease of
their mediastinal nodal disease (documented by mediasti-
noscopy before treatment) after induction chemotherapy.
These 3 patients have enjoyed a median disease-free sur-
vival of 8.6 years. Other patients with enlarged mediastinal
lymph nodes who did not have pretreatment histologic
confirmation of N2 disease but were downstaged by induc-
tion treatment were excluded from the study. This would
bias our results by excluding the subset of patients with IIIA
disease who had a good response to induction therapy,
which would tend to minimize the differences observed
between the group undergoing resection alone versus the
multimodality therapy group. Because we found a signifi-
cant survival improvement with multimodality therapy, the
true survival advantage might indeed be greater than we
have presented here.
In conclusion, we have demonstrated that survival after
resection of patients with stage IIIA (N2) NSCLC disease
has increased in the more recent patient study group. Our
results confirm improved prognosis with female sex, upper
lobe tumor location, R0 resection, involvement of only a
single N2 nodal station, and addition of multimodality ther-
n alone [n  116] vs preoperative or postoperative
ls are displayed. Solid lines, preoperative or postop-
.entio
terva
aloneapy to resection. The distribution of these favorable prog-
and Cardiovascular Surgery ● Volume 130, Number 6 1607
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exception of multimodality therapy, which was used more
extensively in the contemporary era. Thus the survival im-
provement we observed appears to be associated with in-
creased use of multimodality therapy.
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Discussion
Dr Valerie W. Rusch (New York, NY). This excellent analysis of
the factors that influence the outcome of patients with stage IIIA
N2 non–small cell lung cancer (NSCLC) who undergo surgical
resection confirms several important findings that have been iden-
tified in previous retrospective studies and in clinical trials with
this group of patients, namely that overall survival is influenced by
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TSpatient sex, by tumor location, by the completeness of resection,
and by the extent of nodal disease.
The favorable effect of chemotherapy on survival is consistent
with 3 previous small randomized trials that showed improved
outcome with induction chemotherapy and more recent large ran-
domized trials that have shown improved outcome with adjuvant
chemotherapy. These findings support the notion that combined
modality therapy is now the standard of care for patients with stage
IIIA NSCLC.
Other studies have also found improving outcomes in stage
IIIA NSCLCs treated in a multimodality manner. For instance, an
improvement in overall survival has been observed in the North
American randomized intergroup trial for stage IIIA lung cancers,
the so-called intergroup trial 0139, a trial that compared induction
chemoradiotherapy plus surgical intervention with high-dose che-
moradiotherapy without surgical intervention. Relative to the
phase II trial that preceded it, the SWOG 8805 trial, which offered
patients the same induction therapy, the overall survival in both
arms of the 0139 trial has been considerably better, approximately
30% at 5 years.
During the past decade, there have been improvements in
staging that, of course, affect patient selection for surgical inter-
vention. We have also seen the development of better tolerated and
more effective chemotherapy regimens and increasing expertise in
the delivery of multimodality treatment. In addition, there has been
an ongoing shift in the sex distribution of our lung cancer patient
population with a steadily increasing proportion of women. Be-
cause female sex has been consistently identified as a favorable
prognostic factor in all major lung cancer trials, this population
shift alone probably accounts for some of the improvement in
survival, even though it was not identified as the dominant factor
influencing survival over time in this study from MD Anderson. It
is important that we bear these issues in mind as we perform and
analyze future studies in this group of patients with lung cancer.
I think that all thoracic surgeons intuitively understand why
pathologically complete or R0 resection and single versus multi-
level N2 disease affect survival. However, I would appreciate you
commenting further on several aspects of your study.
Do you have any insight as to why patients who have middle or
lower lobe tumors have a worse prognosis?
Second, other studies, including our own from Memorial
Sloan-Kettering and the intergroup 0139 trial, have reported a high
operative mortality for pneumonectomies after induction therapy,
especially right pneumonectomies. Did you analyze right versus
left pneumonectomies, and do you have any insight as to why you
did not observe this particularly high operative mortality in your
study?
Third, the multimodality therapy given in your study was
predominantly adjuvant postoperative radiation. In light of other
studies that have failed to show a survival benefit and perhaps even
a detrimental effect on survival from adjuvant radiation, have you
modified your approach to treatment? What do you consider the
preferred type and sequence of multimodality therapy and why?
Finally, although the use of mediastinoscopy has increased at
MD Anderson during this study, I noted that only one third of
patients underwent mediastinoscopy during the latter part of the
study, and only 5% had a positron emission tomographic scan
performed. Could you perhaps comment on how your analysis has
The Journal of Thoracicaffected your use of these 2 staging modalities in the approach to
multimodality therapy.
Thank you for the privilege of allowing me to comment on this
excellent article.
Dr Martin. Thank you for your comments, Dr Rusch. Your
first question as to why patients with lower or middle lobe tumor
resection have a worse prognosis is a good question, but I cannot
answer that from our study.
In terms of our operative mortality for pneumonectomies, we
did look at this because of the publication from your institution,
and overall, in our study there were 89 pneumonectomies, and the
mortality rate for all patients undergoing pneumonectomy in our
study was 9%. We did look at the patients who had induction
therapy followed by a pneumonectomy, and there were only 13
who met this criterion. There was one death in that group, leading
to a mortality rate of 7.7%. Because of the very small size of that
sample, we did not compare right versus left, but again, our
mortality was not as high. It might be that there were different
combinations of chemotherapy used that might have affected the
pulmonary morbidity and mortality, but we do not have a great
explanation for why that was different.
As far as our use of adjuvant postoperative radiation therapy,
we were surprised by our results that radiation itself in addition to
surgical intervention did yield a better survival. The median sur-
vival was 23 months compared with 15.9 months with surgical
intervention alone, and this was a novel finding. Other studies,
including the PORT trial, have shown potentially lower rates of
local recurrence but no definite survival benefits. I think this is
something that does need to be studied further. We have not
changed our use of adjuvant therapy. We still use it fairly routinely
for patients with N2 disease on final pathology if they have a good
performance status.
As for our ideal sequence of treatment at this point in time, it
is ideal to identify patients with N2 disease before resection, in
which case we would prefer to give induction chemotherapy
followed by surgical intervention. If there is residual N2 disease at
the time of the operation, we would treat with postoperative
radiation therapy. In patients for whom we cannot identify the N2
disease preoperatively, we would give consideration for chemo-
therapy postoperatively.
As far as our mediastinoscopy rates, only 32% of our patients
had mediastinoscopy in the contemporary era. However, looking at
the clinical stages of our patients in that era, 50% were clinically
N0 and another 15% were clinically N1, which leaves about 35%
that were clinically N2, and our rate of mediastinoscopy was
approximately 32%. Therefore we were doing mediastinoscopies
on most patients with clinical N2 disease.
As far as positron emission tomographic scan use, that was a
fairly new modality and just came into use in the last couple of
years, and our study period ended in 2001. Therefore only 10
patients in our total study time had a positron emission tomo-
graphic scan. Because of this, I cannot comment on our use of that
in the study, but we are using it on almost all patients at this point
in time.
Dr Frank Detterbeck (Chapel Hill, NC). You have analyzed
patients on the basis of a variable that you really know postoper-
atively, namely pathologic N2 disease. I always find it a little bit
difficult to take that sort of data and then apply it to a new set of
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I was wondering whether you could characterize the population a
little bit more on the basis of preoperative variables. You started to
hint at that. How many patients had clinically staged N0 or N1
disease? How many patients had a preoperative mediastinoscopy
that demonstrated N2 disease and yet went on to resection anyway
versus patients who had a negative mediastinoscopy but then had
an incidental N2 disease? That would help me in applying this
prospectively.
Dr Martin. Yes, it is difficult to draw conclusions from our
pathologic N2 stage. The reason we chose to use that as a criteria
was that the clinical staging is so unreliable, and therefore to be
certain we were dealing with patients with IIIA N2 disease, we
chose to use pathologic staging as our inclusion criteria. As I
mentioned, the distribution of clinical staging was actually un-
changed over time. There were about 50% who had clinical N0
disease in both eras and another 15% or so who had clinical N1
disease.
As far as the number of patients who had mediastinoscopy-
confirmed N2 disease, I do not have that figure available, but our
approach was that as long as the patient did not have bulky N2
disease, we proceeded with resection in hopes of treating the
patients postoperatively with adjuvant therapy.
Dr Mark J. Krasna (Baltimore, Md). Linda, that was an
excellent presentation. I have just one specific question. If you are
going to use mediastinoscopy on patients to determine IIIA disease
before treatment, one of the findings from the last several years’
series, both the Brigham and our place, is that persistent positive
mediastinal disease is a poor indicator. In other words, mediastinal
clearance on its own might be a very important prognosticator. Can
you perhaps comment on how you and your group will use this in
the future now that you are going to hopefully use multimodality
therapy? Thank you.
Dr Martin. A couple of things. First of all, we did have 3
patients in our study who had a mediastinoscopy showing N2
1610 The Journal of Thoracic and Cardiovascular Surgery ● Decdisease. They then had induction therapy, and the final pathology
showed complete clearance of the N2 nodes. That was only 3
patients out of our entire group. Those patients did have a much
longer survival, but it was such a small number that it is hard to
compare them with the rest.
Definitely, persistent nodal disease is a bad prognostic indica-
tor, but our study consisted entirely of patients with N2 disease at
the time of resection, and we believe that we achieved reasonably
good survival results given that circumstance. Again, if we can
identify the N2 disease beforehand and treat it, that is the best
possible situation, but even when we cannot, we still think we can
achieve reasonable results with resection followed by adjuvant
treatment.
Dr Stephen D. Cassivi (Rochester, Minn). Linda, that was a
great presentation, and I commend you for the work you have
done. My question to you with regard to multimodality therapy is
as follows. I think we all have the inclination that that is an
important part of the treatment for patients with this stage of
disease. My question to you is this: Because of the nature of your
retrospective study, I wonder whether some of the effect that you
are attributing to multimodality therapy is, however, due to per-
haps a bit of selection bias because most of your patients who got
multimodality therapy got adjuvant radiation therapy, and I won-
der whether there was a selection bias for those patients who were
more likely to tolerate such a therapy, and therefore those who
would not be likely to tolerate it were in the group that did not get
it and had worse survival?
Dr Martin. Thank you. Certainly there could be selection bias.
It is very difficult to determine how these decisions were made in
a retrospective review, and there might be patients who had in-
duction therapy and had a poor performance status and were not
treated with surgical intervention or patients with bulky N2 disease
who did not undergo resection, and therefore they did not show up
in our patient population. Therefore there could be patient selec-
tion, but I cannot be certain to what extent that occurred.
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TSFigure E1. Survival comparing preoperative or postoperative chemotherapy (n  81) versus surgical intervention
alone (n  116). Ninety-five percent confidence intervals are displayed. Solid lines, preoperative or postoperative
chemotherapy; dashed lines, surgical intervention alone.
Figure E2. Survival comparing surgical intervention followed by radiation therapy (XRT; n  156) with surgical
intervention alone (n  116). Ninety-five percent confidence intervals are displayed. Solid lines, postoperative
radiation therapy; dashed lines, surgical intervention alone.
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intervals are displayed. Solid lines, R0; dashed lines, R1 or R2.1610.e2 The Journal of Thoracic and Cardiovascular Surgery ● December 2005
